K-RasV14I-induced Noonan syndrome predisposes to tumour development in mice

Journal of Pathology

Volumn 239, Issue 2, 2016, Pages 206-217

  Hernández Porras, Isabel ^a   Schuhmacher, Alberto J ^a   Garcia Medina, Raquel ^a   Jiménez, Beatriz ^a   Cañamero, Marta ^a,b   De Martino, Alba ^a   Guerra, Carmen ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

cancer; K Ras; Noonan syndrome; RASopathies

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; K RAS V141 PROTEIN; UNCLASSIFIED DRUG; KRAS2 PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN P21;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHRONIC PANCREATITIS; CONTROLLED STUDY; FIBROSARCOMA; GENE MUTATION; HISTIOCYTIC SARCOMA; LEUKEMIA; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; NOONAN SYNDROME; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ALLELE; AMINO ACID SUBSTITUTION; ANIMAL; C57BL MOUSE; CONGENITAL HEART MALFORMATION; DISEASE MODEL; DISEASE PREDISPOSITION; FEMALE; GENETICS; HETEROZYGOTE DETECTION; HUMAN; LUNG TUMOR; MALE; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY;

ALLELES; AMINO ACID SUBSTITUTION; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; FEMALE; HEART DEFECTS, CONGENITAL; HETEROZYGOTE DETECTION; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MUTATION; NEOPLASMS; NOONAN SYNDROME; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84971612091     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4719     Document Type: Article

References (53)

1. Schubbert S, Shannon K, Bollag G,. Hyperactive Ras in developmental disorders and cancer. Nature Rev Cancer 2007; 7: 295-308.
2. Fernandez-Medarde A, Santos E,. Ras in cancer and developmental diseases. Genes Cancer 2011; 2: 344-358.
3. Rauen KA,. The RASopathies. Annu Rev Genomics Hum Genet 2013; 14: 355-369.
4. Roberts AE, Allanson JE, Tartaglia M, et al., Noonan syndrome. Lancet 2013; 381: 333-342.
5. Aoki Y, Niihori T, Banjo T, et al., Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet 2013; 93: 173-180.
6. Flex E, Jaiswal M, Pantaleoni F, et al., Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum Mol Genet 2014; 23: 4315-4327.
7. Tartaglia M, Gelb BD, Zenker M,. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab 2011; 25: 161-179.
8. Kwon MC, Berns A,. Mouse models for lung cancer. Mol Oncol 2013; 7: 165-177.
9. Gripp KW,. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 2005; 137C: 72-77.
10. Niemeyer CM,. RAS diseases in children. Haematologica 2014; 99: 1653-1662.
11. Jongmans MC, van der Burgt I, Hoogerbrugge PM, et al., Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur J Hum Genet 2011; 19: 870-874.
12. Smpokou P, Zand DJ, Rosenbaum KN, et al., Malignancy in Noonan syndrome and related disorders. Clin Genet 2015; 88: 516-522.
13. Kratz CP, Rapisuwon S, Reed H, et al., Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 2011; 157C: 83-89.
14. Kratz CP, Franke L, Peters H, et al., Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer 2015; 112: 1392-1397.
15. V14I recapitulates Noonan syndrome in mice. Proc Natl Acad Sci U S A 2014; 111: 16395-16400.
16. Guerra C, Mijimolle N, Dhawahir A, et al., Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003; 4: 111-120.
17. Guerra C, Schuhmacher AJ, Canamero M, et al., Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007; 11: 291-302.
18. Serrano M, Lee H, Chin L, et al., Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85: 27-37.
19. Donehower LA, Harvey M, Slagle BL, et al., Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
20. Simpson AJ, Wallace WA, Marsden ME, et al., Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J Immunol 2001; 167: 1778-1786.
21. Hernandez-Porras I, Jimenez- Catalan B, Schuhmacher AJ, et al. The impact of genetic backgrounds in the K-RasV14I-induced Noonan syndrome. Rare Diseases 2015; e1045169.
22. Quaio CR, Carvalho JF, da Silva CA, et al., Autoimmune disease and multiple autoantibodies in 42 patients with RASopathies. Am J Med Genet A 2012; 158A: 1077-1082.
23. Forbes SA, Bindal N, Bamford S, et al., COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950.
24. G12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004; 5: 375-387.
25. Jackson EL, Willis N, Mercer K, et al., Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
26. Johnson L, Mercer K, Greenbaum D, et al., Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410: 1111-1116.
27. Mainardi S, Mijimolle N, Francoz S, et al., Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci U S A 2013; 111: 255-260.
28. Almoguera C, Shibata D, Forrester K, et al., Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554.
29. Hezel AF, Kimmelman AC, Stanger BZ, et al., Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218-1249.
30. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
31. Guerra C, Barbacid M,. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol 2013; 7: 232-247.
32. Hingorani SR, Petricoin EF, Maitra A, et al., Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450.
33. Malka D, Hammel P, Maire F, et al., Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002; 51: 849-52.
34. Guerra C, Collado M, Navas C, et al., Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011; 19: 728-739.
35. Maitra A, Hruban RH,. Pancreatic cancer. Annu Rev Pathol 2008; 3: 157-188.
36. Zhang Z, Wang Y, Vikis HG, et al., Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature Genet 2001; 29: 25-33.
37. Diaz R, Ahn D, Lopez-Barcons L, et al., The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 2002; 62: 4514-4518.
38. Grabocka E, Pylayeva-Gupta Y, Jones MJ, et al., Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 2014; 25: 243-256.
39. Gremer L, Merbitz-Zahradnik T, Dvorsky R, et al., Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat 2011; 32: 33-43.
40. Schubbert S, Zenker M, Rowe SL, et al., Germline KRAS mutations cause Noonan syndrome. Nature Genet 2006; 38: 331-336.
41. Schubbert S, Bollag G, Lyubynska N, et al., Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol 2007; 27: 7765-7770.
42. Lo FS, Lin JL, Kuo MT, et al., Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature. Eur J Pediatr 2009; 168: 919-923.
43. G12D from the endogenous locus. Blood 2011; 117: 2022-2032.
44. Leventopoulos G, Denayer E, Makrythanasis P, et al., Noonan syndrome and systemic lupus erythematosus in a patient with a novel KRAS mutation. Clin Exp Rheumatol 2010; 28: 556-557.
45. Aguirre AJ, Bardeesy N, Sinha M, et al., Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-3126.
46. Ji H, Ramsey MR, Hayes DN, et al., LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-810.
47. Jackson EL, Olive KP, Tuveson DA, et al., The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005; 65: 10280-10288.
48. G12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-483.
49. Li J, Zhang Z, Plass C, et al., LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene 2003; 22: 1243-1246.
50. Puyol M, Martin A, Dubus P, et al., A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010; 18: 63-73.
51. Estep AL, Tidyman WE, Teitell MA, et al., HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 2006; 140: 8-16.
52. G12V induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A 2009; 106: 7979-7984.
53. Schuhmacher AJ, Guerra C, Sauzeau V, et al., A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest 2008; 118: 2169-2179.